Alexandra Winters1, Bruno Ramos-Molina2, Timothy S Jarvela2, Laura Yerges-Armstrong3, Toni I Pollin3, Iris Lindberg4. 1. Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD 21201, United States; Division of Endocrinology, Diabetes, and Nutrition, University of Maryland School of Medicine, Baltimore, MD 21201, United States. 2. Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD 21201, United States. 3. Division of Endocrinology, Diabetes, and Nutrition, University of Maryland School of Medicine, Baltimore, MD 21201, United States. 4. Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD 21201, United States. Electronic address: ilindberg@som.umaryland.edu.
Abstract
AIMS: In humans, noncoding variants of PCSK2, the gene encoding prohormone convertase 2 (PC2), have been previously associated with risk for and age of onset of type 2 diabetes (T2D). The aims of this study were to identify coding variants in PCSK2; to determine their possible association with glucose handling; and to determine functional outcomes for coding variants in biochemical studies. METHODS: Exome-wide genotyping was performed on 1725 Old Order Amish (OOA) subjects. PCSK2 coding variants were tested for association with diabetes-related phenotypes. In vitro analyses using transfected human PC2-encoding constructs were performed to determine the impact of each mutation on PC2 activity. RESULTS: We identified 10 rare missense coding variants in PCSK2 in various genomic databases. R430W (rs200711626) is greatly enriched in the OOA population (MAF 4.3%). This variant is almost twice as common (MAF 7.4%) in OOA individuals with T2D as in OOA individuals with normal or with normal/impaired glucose tolerance (MAF 3.9% and 2.9%, respectively; p=0.25 and p=0.10). In vitro experiments revealed a broadening of the pH optimum for the R430W variant, which may result in increased activity against PCSK2 substrates. CONCLUSIONS: Although the association of the R430W variation with T2D in the OOA population did not reach significance, based upon the broadened pH profile of R430W PC2, we speculate that the presence of this substitution may result in altered processing of PCSK2 substrates, ultimately leading to increased conversion to diabetes.
AIMS: In humans, noncoding variants of PCSK2, the gene encoding prohormone convertase 2 (PC2), have been previously associated with risk for and age of onset of type 2 diabetes (T2D). The aims of this study were to identify coding variants in PCSK2; to determine their possible association with glucose handling; and to determine functional outcomes for coding variants in biochemical studies. METHODS: Exome-wide genotyping was performed on 1725 Old Order Amish (OOA) subjects. PCSK2 coding variants were tested for association with diabetes-related phenotypes. In vitro analyses using transfected humanPC2-encoding constructs were performed to determine the impact of each mutation on PC2 activity. RESULTS: We identified 10 rare missense coding variants in PCSK2 in various genomic databases. R430W (rs200711626) is greatly enriched in the OOA population (MAF 4.3%). This variant is almost twice as common (MAF 7.4%) in OOA individuals with T2D as in OOA individuals with normal or with normal/impaired glucose tolerance (MAF 3.9% and 2.9%, respectively; p=0.25 and p=0.10). In vitro experiments revealed a broadening of the pH optimum for the R430W variant, which may result in increased activity against PCSK2 substrates. CONCLUSIONS: Although the association of the R430W variation with T2D in the OOA population did not reach significance, based upon the broadened pH profile of R430WPC2, we speculate that the presence of this substitution may result in altered processing of PCSK2 substrates, ultimately leading to increased conversion to diabetes.
Authors: Ming Liu; Israel Hodish; Leena Haataja; Roberto Lara-Lemus; Gautam Rajpal; Jordan Wright; Peter Arvan Journal: Trends Endocrinol Metab Date: 2010-08-18 Impact factor: 12.015
Authors: R S Jackson; J W Creemers; S Ohagi; M L Raffin-Sanson; L Sanders; C T Montague; J C Hutton; S O'Rahilly Journal: Nat Genet Date: 1997-07 Impact factor: 38.330
Authors: Gregory M Cooper; Eric A Stone; George Asimenos; Eric D Green; Serafim Batzoglou; Arend Sidow Journal: Genome Res Date: 2005-06-17 Impact factor: 9.043
Authors: Huw B Jones; Jaimini Reens; Simon R Brocklehurst; Catherine J Betts; Sue Bickerton; Alison L Bigley; Richard P Jenkins; Nicky M Whalley; Derrick Morgan; David M Smith Journal: Int J Exp Pathol Date: 2014-02 Impact factor: 1.925
Authors: Dorota Kowalska; Jin Liu; Jon R Appel; Akihiko Ozawa; Adel Nefzi; Robert B Mackin; Richard A Houghten; Iris Lindberg Journal: Mol Pharmacol Date: 2008-12-12 Impact factor: 4.436
Authors: Nabila Bouatia-Naji; Vincent Vatin; Cécile Lecoeur; Barbara Heude; Christine Proença; Jacques Veslot; Béatrice Jouret; Jean Tichet; Guillaume Charpentier; Michel Marre; Beverley Balkau; Philippe Froguel; David Meyre Journal: BMC Med Genet Date: 2007-07-07 Impact factor: 2.103